Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia/Ib study to evaluate the taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer

Next Previous
Trial Profile

A phase Ia/Ib study to evaluate the taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taselisib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 21 Sep 2017 Status changed from active, no longer recruiting to completed.
  • 18 Mar 2017 Results (n=171) of retrospective pooled analysis of PMT4979g and JO29196 trials assessing effect of acid reducing agent on PK of taselisib, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 30 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top